Navigation Links
PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
Date:9/9/2013

INCLINE VILLAGE, Nev., Sept. 9, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2013, of approximately $97 million, as compared with actual revenue of $85 million for the third quarter of 2012, an approximate 14 percent increase.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO )

The forecasted growth in revenues is driven by increased second quarter 2013 sales for Avastin®, Herceptin®, Lucentis®, Xolair®, Kadcyla®, Perjeta®, and Actemra® for which PDL receives royalties in the third quarter of 2013.  Sales of Avastin®, Herceptin®, Lucentis®, Xolair®, Perjeta®, and Kadcyla® (the Genentech Products) are subject to a tiered royalty rate for product that is made or sold in the United States and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States (ex-US manufactured and sold).  The net sales thresholds and the applicable royalty rates for the Genentech Products are outlined below:   Genentech Products Made or Sold in US

Royalty RateNet sales up to $1.5 billion

3.0%Net sales between $1.5 billion and up to $2.5 billion

2.5%Net sales between $2.5 billion and up to $4.0 billion

2.0%Net sales exceeding $4.0 billion

1.0%Genentech Products Made and Sold ex-USNet sales

3.0%The third quarter royalty payment received from Genentech included royalties based on worldwide sales.

Revenue guidance for the third quarter of 2013 is net of an estimated payment due under our February 2011 settlement agreement with Novartis AG (Novartis). PDL pays to Novartis certain amounts based on net sales of Lucentis, made by Novartis, during calendar year 2011 and beyond. The amount paid is less than we receive in royalties on such sales.

Reported worldwide sales for Avastin increased approximately 13 percent in the second quarter of 2013 when compared to the same period in 2012.  Ex-U.S. manufactured and sold Avastin sales represented 38 percent of total Avastin sales in the second quarter of 2013 as compared with 29 percent in the second quarter of 2012.

Reported worldwide sales for Herceptin increased approximately 1 percent in the second quarter of 2013 when compared to the same period in 2012. Ex-U.S. manufactured and sold Herceptin sales represented 38 percent of total Herceptin sales in the second quarter of 2013 as compared with 37 percent in the second quarter of 2012.

Reported worldwide sales for Lucentis increased approximately 9 percent in the second quarter of 2013 when compared to the same period in 2012. All sales of Lucentis were from inventory produced in the United States.

Reported worldwide sales for Tysabri®, a Biogen Idec product, decreased approximately 1 percent for the second quarter of 2013 compared to the same period in 2012. Tysabri royalties are determined at a flat rate as a percentage of sales regardless of location of manufacture or sale.

The sales information presented above is based on information provided by PDL's licensees in their quarterly reports to the Company as well as from public disclosures made by PDL's licensees.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements
This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus made or sold in the U.S.;
  • The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
  • The productivity of acquired income generating assets may not fulfill our revenue forecasts and, if secured by collateral, we may be undersecured and unable to recuperate our capital expenditures in the transaction;
  • Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
  • The outcome of pending litigation or disputes, including PDL's current dispute with Genentech related to ex-U.S. sales of Genentech licensed products;
  • The change in foreign currency exchange rate;
  • Positive or negative results in PDL's attempt to acquire income generating assets; and
  • The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.
  • Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual report filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.


    '/>"/>
    SOURCE PDL BioPharma, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
    2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
    3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
    4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
    6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    7. S1 Biopharma Expands Focus to Include Male Sexual Health
    8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
    9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
    10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
    11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2017)... 22, 2017  Lilac Corp, the company that ... launch of a new website . The ... a clinical study that showed surprising clearance of ... in individuals suffering from HPV warts, precancerous, or ... are no other treatments that clear the virus. ...
    (Date:5/18/2017)... 2017  Two Bayer U.S. Pharmaceutical leaders received top ... recent 28 th Woman of the Year ... HBA,s longstanding mission of furthering the advancement and impact ... Cindy Powell-Steffen , senior director of brand activation ... Libby Howe , a regional business manager for ...
    (Date:5/15/2017)... ATLANTA , May 15, 2017  Amy Baxter ... the industry leader in noninvasive pain relief, was awarded ... MM&M magazine. Baxter was recognized at the MM&M ... New York City on May 10, ... helping the biopharma industry go "beyond the pill."  ...
    Breaking Medicine Technology:
    (Date:6/25/2017)... ... June 25, 2017 , ... An increase in wetter weather in the ... and along with that; a humdinger of an allergy season. A relief from drought ... increase in misery-causing grass and weed pollen. , “Our patients have been reporting ...
    (Date:6/24/2017)... ... 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) ... Erie Convention Center on June 8-10. The weekend consisted of many educational ... and scholarship presentations, and professional networking. , On Friday June 9th, PATS ...
    (Date:6/23/2017)... ... June 23, 2017 , ... "The Better ... ultimately do significant harm to people with all chronic conditions, including mental illnesses, ... leaves in place the Affordable Care Act (ACA) requirement that insurers cover pre-existing ...
    (Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. Rubinstein ... recently begun offering three new minimally invasive procedures to patients who want a ... downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich ...
    (Date:6/23/2017)... ... June 23, 2017 , ... ... essential, and two new videos highlight the importance of correctly using a meat ... Ph.D., who has done extensive research on consumer food safety habits. Dr. Bruhn ...
    Breaking Medicine News(10 mins):